WallStreetZenWallStreetZen

NASDAQ: GYRE
Gyre Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for GYRE

Based on 2 analysts offering 12 month price targets for Gyre Therapeutics Inc

Min Forecast
$16.00+111.36%
Avg Forecast
$17.00+124.57%
Max Forecast
$18.00+137.78%

Should I buy or sell GYRE stock?

Based on 2 analysts offering ratings for Gyre Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Buy" agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their GYRE stock forecasts and price targets.

GYRE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-10
lockedlocked$00.00+00.00%2025-08-26

1 of 1

Forecast return on equity

Is GYRE forecast to generate an efficient return?

Company
64.59%
Industry
352.37%
Market
209.24%
GYRE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GYRE forecast to generate an efficient return on assets?

Company
41.31%
Industry
118.97%
GYRE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GYRE earnings per share forecast

What is GYRE's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.19+172%
Avg 2 year Forecast
$0.07+2%
Avg 3 year Forecast
$2.32+3,207.71%

GYRE revenue forecast

What is GYRE's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$149.1M+38.96%
Avg 2 year Forecast
$149.8M+39.69%
Avg 3 year Forecast
$452.0M+321.35%
GYRE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GYRE revenue growth forecast

How is GYRE forecast to perform vs Biotechnology companies and vs the US market?

Company
53.3%
Industry
112.94%
Market
22.91%
GYRE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GYRE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GYRE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GYRE$7.57$17.00+124.57%Strong Buy
CTMX$4.26$7.25+70.19%Strong Buy
ATXS$12.98$24.20+86.44%Buy
PROK$2.36$9.00+281.36%Strong Buy
PRME$3.92$6.63+69.01%Buy
View Top Biotech Stocks

Gyre Therapeutics Stock Forecast FAQ

Is Gyre Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: GYRE) stock is to Strong Buy GYRE stock.

Out of 2 analysts, 1 (50%) are recommending GYRE as a Strong Buy, 1 (50%) are recommending GYRE as a Buy, 0 (0%) are recommending GYRE as a Hold, 0 (0%) are recommending GYRE as a Sell, and 0 (0%) are recommending GYRE as a Strong Sell.

If you're new to stock investing, here's how to buy Gyre Therapeutics stock.

What is GYRE's earnings growth forecast for 2026-2028?

(NASDAQ: GYRE) Gyre Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.52%.

Gyre Therapeutics's earnings in 2026 is $6,651,000.On average, 5 Wall Street analysts forecast GYRE's earnings for 2026 to be $18,341,833, with the lowest GYRE earnings forecast at $1,888,130, and the highest GYRE earnings forecast at $43,494,420. On average, 4 Wall Street analysts forecast GYRE's earnings for 2027 to be $6,878,187, with the lowest GYRE earnings forecast at -$8,496,584, and the highest GYRE earnings forecast at $23,264,457.

In 2028, GYRE is forecast to generate $223,049,792 in earnings, with the lowest earnings forecast at $214,302,741 and the highest earnings forecast at $229,610,080.

What is GYRE's revenue growth forecast for 2026-2028?

(NASDAQ: GYRE) Gyre Therapeutics's forecast annual revenue growth rate of 53.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 112.94%, and while it is forecast to beat the US market's average forecast revenue growth rate of 22.91%.

Gyre Therapeutics's revenue in 2026 is $107,265,000.On average, 5 Wall Street analysts forecast GYRE's revenue for 2026 to be $14,359,420,382, with the lowest GYRE revenue forecast at $10,799,910,231, and the highest GYRE revenue forecast at $20,027,663,340. On average, 4 Wall Street analysts forecast GYRE's revenue for 2027 to be $14,434,560,245, with the lowest GYRE revenue forecast at $12,253,577,570, and the highest GYRE revenue forecast at $16,588,569,635.

In 2028, GYRE is forecast to generate $43,538,733,638 in revenue, with the lowest revenue forecast at $41,831,710,096 and the highest revenue forecast at $44,819,964,626.

What is GYRE's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: GYRE) forecast ROA is 41.31%, which is lower than the forecast US Biotechnology industry average of 118.97%.

What is GYRE's Price Target?

According to 2 Wall Street analysts that have issued a 1 year GYRE price target, the average GYRE price target is $17.00, with the highest GYRE stock price forecast at $18.00 and the lowest GYRE stock price forecast at $16.00.

On average, Wall Street analysts predict that Gyre Therapeutics's share price could reach $17.00 by Oct 10, 2026. The average Gyre Therapeutics stock price prediction forecasts a potential upside of 124.57% from the current GYRE share price of $7.57.

What is GYRE's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: GYRE) Gyre Therapeutics's current Earnings Per Share (EPS) is $0.07. On average, analysts forecast that GYRE's EPS will be $0.19 for 2026, with the lowest EPS forecast at $0.02, and the highest EPS forecast at $0.45. On average, analysts forecast that GYRE's EPS will be $0.07 for 2027, with the lowest EPS forecast at -$0.09, and the highest EPS forecast at $0.24. In 2028, GYRE's EPS is forecast to hit $2.32 (min: $2.22, max: $2.38).

What is GYRE's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: GYRE) forecast ROE is 64.59%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.